IMCR Immunocore Holdings plc — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$34.48

Period return

-0.55 (-1.57%)

Volume

477.6K

2026-07-21O $33.65 H $34.5 L $33.35 C $34.48MA5 $34.53MA20 $32.48MA60 $30.06MA120 $30.85

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 06.Highin 16 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 04. 21.LowBUY3 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 04. 15.LowBUY3 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 03. 16.MediumHOLD4 months ago
Jefferies: Hold
US analyst rating / recommendation change.
2026. 02. 26.LowBUY5 months ago
Needham: Buy
US analyst rating / recommendation change.
2026. 02. 04.LowBUY6 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 11. 11.LowHOLD8 months ago
Morgan Stanley: Equal-Weight
US analyst rating / recommendation change.
2025. 11. 01.MediumBUY9 months ago
Wells Fargo: Overweight
US analyst rating / recommendation change.
2025. 10. 23.LowBUY9 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 06. 02.LowBUYlast year
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $63.49 · 13 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Sector: Healthcare
Industry

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 06.	After market close (AMC)	$0.02	—	—	$110.31M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$0.1	—	—	$93.88M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-0.55	—	—	$226.15M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-0.72	—	—	$145.9M	Reported

Immunocore Holdings plc

Price chart

Recent event timeline

Recent earnings

Research actions

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 04. 21.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 04. 15.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 03. 16.	Jefferies	—	Downgrade	Buy → Hold	—	Jefferies: Buy → Hold
2026. 02. 26.	Needham	—	Maintain	Buy → Buy	—	Needham: Buy
2026. 02. 04.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2025. 11. 11.	Morgan Stanley	—	Maintain	Equal-Weight → Equal-Weight	—	Morgan Stanley: Equal-Weight